Department of Neurology, Emory University, Woodruff Memorial Research Building, 101 Woodruff Circle, Suite 6000, Atlanta, GA 30322, USA.
Neurology. 2011 Sep 27;77(13):1305-7. doi: 10.1212/WNL.0b013e318230a18f.
Using data from NIH Research Portfolio Online Reporting Tools (RePORT) and recently assembled prevalence estimates of 6 major neurologic diseases, we compared the relative prevalences and the annual NIH support levels for 6 major neurologic disorders: Alzheimer disease, amyotrophic lateral sclerosis (ALS), epilepsy, multiple sclerosis, Parkinson disease, and stroke. Compared to these other major neurologic disorders, epilepsy research is funded at a persistently lower rate based on relative disease prevalences. Relative NIH funding for these other disorders in 2010 adjusted for prevalence ranged from 1.7x (stroke) to 61.1x (ALS) greater than epilepsy. The disparity cannot be explained by differences in the overall impact of these diseases on US citizens. Greater transparency in the review and funding process is needed to disclose the reason for this disparity.
利用美国国立卫生研究院研究组合在线报告工具（RePORT）的数据和最近汇总的 6 种主要神经疾病的流行率估计，我们比较了 6 种主要神经疾病（阿尔茨海默病、肌萎缩性侧索硬化症、癫痫、多发性硬化症、帕金森病和中风）的相对流行率和美国国立卫生研究院每年的支持水平。与这些其他主要神经疾病相比，癫痫研究的资金支持率一直基于相对疾病流行率较低。2010 年，根据流行率调整后的这些其他疾病的相对 NIH 资金支持范围从癫痫的 1.7 倍（中风）到 61.1 倍（肌萎缩性侧索硬化症）不等。这种差异不能用这些疾病对美国公民的总体影响的差异来解释。需要提高审查和资助过程的透明度，以揭示这种差异的原因。
